(1 - 13 from 41
)
Bispecific Antibodies Close in on Cancer - Genetic Engineering and ...www.genengnews.com › Insights
www.genengnews.com
Feb 27, · “There's now a large heterogeneity of products out there in the market” said Neil Brewis, Ph.D., the chief scientific officer of F-star ...
F-Star wins over $1.52bn from blockbuster Janssen deal - Business ...www.businessweekly.co.uk › news › biomedtech
www.businessweekly.co.uk
Oct 20, · Neil Brewis, chief scientific officer of F-star said: “We are pleased to collaborate with Janssen and leverage the science of F-star's ...
F-star Presents New Data on OX40/CD137 Tetravalent Bispecific ...apnews.com › ...
apnews.com
Nov 8, · Neil Brewis, CSO of F-star said“Recent clinical trials involving agonist molecules have reported that a meaningful anti-cancer response is ...
F-star Selects Genedata Biologics for Immuno-Oncology ...www.genedata.com › news › details › f-star-selects-genedata-biologics
www.genedata.com
Nov 15, · ... the market and quickly came to the conclusion that Genedata Biologics would suit our needs,” said Dr. Neil Brewis, CSO of F-star.
sorted by relevance / date